{"title": "A new transmission route for the propagation of the SARS-CoV-2 coronavirus", "doi": "10.1101/2020.02.14.20022939", "citation_id": "2020.02.14.20022939v1", "date": "2020-02-18", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.14.20022939", "abstract": "<p>We explore here how variation in the SARS-CoV-2 virus tropism could influence epidemic spread. We use a compartmental model fit to the existing data. The model\nindicates that Wuhan quarantine measures were effective but that alternative virus forms (gut tropism) and a second propagation route (through environment) was\npresent. For Singapore and Shenzhen region the secondary route does not seem to be active yet. Adequate prevention measures taking into account both routes should be implemented.</p>", "twitter_description": "We explore here how variation in the SARS-CoV-2 virus tropism could influence epidemic spread. We use a compartmental model fit to the existing data. The model indicates that Wuhan quarantine measures were effective but that alternative virus forms (gut tropism) and a second propagation route (through environment) was present. For Singapore and Shenzhen region the secondary route does not seem to be active yet. Adequate prevention measures taking into account both routes should be implemented.\n\n### Competing Interest Statement\n\nAD is employed by Stellate Therapeutics (fka Amabiotics), a company that works on treatment of neurodegenerative diseases.\n\n### Funding Statement\n\nAuthors were funded by their respective employers.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nno personal of private data were used in this work.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.14.20022939v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.14.20022939v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.14.20022939v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/18/2020.02.14.20022939.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.14.20022939v1", "access_rights": "restricted", "authors": ["Antoine Danchin", "Tuen Wai Patrick Ng", "Gabriel TURINICI"]}